key: cord-0713091-y5rt0807
authors: Kerget, Ferhan; Kerget, Buğra; İba Yılmaz, Sibel; Kızıltunç, Ahmet
title: Evaluation of the relationship between TREM‐1/TREM‐2 ratio and clinical course in COVID‐19 pneumonia
date: 2021-08-08
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14697
sha: ac001759f4052bea2b99b952b1eca980d0d898d4
doc_id: 713091
cord_uid: y5rt0807

OBJECTIVE: The inflammatory/anti‐inflammatory balance has an important role in the clinical course of SARS‐CoV‐2 infection (COVID‐19), which has affected over 100 million people since it first appeared in China in December 2019. The aim of this study was to investigate the relationship between triggering receptor expressed on myeloid cells (TREM)‐1/TREM‐2 ratio and COVID‐19 severity. METHODS: A total of 171 individuals were included in the study: 121 patients who were admitted to the chest diseases department and intensive care unit of our hospital and diagnosed with COVID‐19 by real‐time PCR of nasopharyngeal swab samples from December 2020 to March 2021 and a control group consisting of 50 asymptomatic health workers in our hospital who had negative real‐time PCR results during routine COVID‐19 screening. RESULTS: TREM‐1 level was significantly higher in patients with severe disease compared with the moderate and control groups (P = .003, P = .001). TREM‐2 levels did not differ significantly in moderate and severe patients (P = .36) but were significantly higher in both patient groups compared with the control group (P = .001 for both). TREM‐1/TREM‐2 ratio was significantly higher in the severe patient group than in the moderate and control groups (P = .001 for both). In receiver operating characteristic curve analysis of TREM‐1/TREM‐2 ratio in patients with moderate and severe COVID‐19, the area under the curve was 0.723. Using a cut‐off value of 0.125 for TREM‐1/TREM‐2 ratio in the Youden index calculation, the sensitivity was 60% and specificity was 71%. CONCLUSION: Experience with the positive effects of medical treatments to restore inflammatory balance in the course of COVID‐19 is steadily increasing. TREM‐1 and TREM‐2 have an important role in inflammation and may serve as biomarkers and therapeutic targets in the early treatment and follow‐up of COVID‐19.

pneumocytes. 2, 3 Overproduction of proinflammatory cytokines can cause endothelial dysfunction in many vital organs, especially the lungs. Proinflammatory cytokines synthesised by T helper cells and macrophages play an important role in this phenomenon, which is referred to as a cytokine storm. 4 The triggering receptor expressed on myeloid cells (TREM) family of immune receptors can be synthesised from many tissues and cells, especially monocytes, macrophages, dendritic cells and neutrophils.

TREM-1 is a member of this family and induces the synthesis of tumour necrosis factor alpha (TNFα), interleukin 1 (IL-1), monocyte chemoattractant protein-1 and IL-6, particularly in inflammatory diseases. 5 Similar to COVID-19, disruption of the inflammatory/ anti-inflammatory balance is important in sepsis. Mouse sepsis studies have shown that suppression of high TREM-1 production with recombinant TREM-1/Fc fusion protein or antagonistic peptides may prevent endotoxemia. However, a moderate concentration of TREM-1 silencer RNA (siRNA) reduced mortality in sepsis while a higher concentration prevented respiratory burst in neutrophils. 6 TREM-2, another member of the TREM family, is also synthesised by macrophages and together with its receptor, DNAXactivating protein of 12 kDa (DAP12), functions to suppress the proinflammatory response. Initial studies with TREM-2 in microglia cells showed that it plays an important role in suppressing TNFα and IL-6 levels. [7] [8] [9] Subsequent studies indicated that TREM-2 is involved in many neurodegenerative diseases, especially Alzheimer's disease.

A substantial portion of the studies investigating TREM-2 pertain to neurological diseases, but there is a paucity of data in the literature on its role in lung parenchymal diseases.

In this study, we aimed to investigate the relationship between serum TREM-1, TREM-2 and TREM-1/TREM-2 ratio and clinical course in COVID-19, in which the inflammatory/anti-inflammatory balance is an important factor.

The study included 121 patients over 18 years of age who were diagnosed as having COVID-19 using real-time polymerase chain reaction (PCR) analysis of a nasopharyngeal swab sample and 50 health workers over 18 years of age who had no symptoms and a negative SARS-CoV-2 PCR result from December 2020 to March 2021.

High-resolution computed tomography (HRCT) was performed routinely in all patients at high risk of COVID-19. Predominantly peripheral bilateral ground-glass opacities, subsegmental consolidation or linear opacities, crazy-paving pattern and reverse halo sign were considered typical HRCT findings. Patients with these findings and patients with radiologically atypical findings but consistent clinical symptoms were hospitalised. Haematological and biochemical parameters including liver and kidney function tests, coagulation parameters, ferritin, D-dimer, troponin-I and C-reactive protein (CRP) were analysed at admission and daily thereafter.

The 171 individuals in the study were divided into three groups. The first group included asymptomatic, PCR-negative health workers who volunteered for the study (n = 50). The second group included patients with moderate illness, defined as clinical signs of pneumonia but no signs of severe pneumonia (respiratory rate ≥30 breaths/ min, SpO 2 ≤ 92%, and/or lung infiltration rate >50%) (n = 68). The third group included patients with severe illness, defined as having signs of severe pneumonia and developing macrophage activation syndrome (MAS) during follow-up (n = 53).

Exclusion criteria were the presence of chronic or clinically significant infectious or inflammatory conditions within the last month, asthma, chronic obstructive pulmonary disease (COPD), malignancy, invasive surgical procedures within the last month, uncontrolled hypertension, high fasting blood glucose, diabetes, cerebrovascular disease, kidney disease and coronary artery disease. Medical history and laboratory parameters obtained at admission were used to evaluate the patients

• The triggering receptor expressed on myeloid cells (TREM) family of immune receptors can be synthesised from many tissues and cells, especially monocytes, macrophages, dendritic cells, and neutrophils.

• TREM-1 is a member of this family and induces the synthesis of tumour necrosis factor alpha (TNFα), interleukin 1 (IL-1), monocyte chemoattractant protein-1 and IL-6, particularly in inflammatory diseases.

• TREM-2, another member of the TREM family, is also synthesised by macrophages and together with its receptor, DNAX-activating protein of 12 kDa (DAP12), functions to suppress the proinflammatory response.

• Initial studies with TREM-2 in microglia cells showed that it plays an important role in suppressing TNFα and IL-6 levels.

• Anti-inflammatory treatments have yielded positive results and increased survival in COVID-19.

• Therefore, medical treatments that suppress TREM-1 synthesis or increase TREM-2 expression may have an important role in preventing disease progression.

• In addition, detecting a high TREM-1/TREM-2 ratio early in the disease may provide early information about progression.

for exclusion criteria. The cardiology, chest diseases and internal medicine departments were consulted regarding the presence of coronary artery disease, asthma, COPD and diabetes.

Fever was defined as an axillary temperature of 37.3°C or higher. In patients with a high fever while under treatment for COVID-19, blood, urine and sputum cultures were obtained to test for possible bacterial and fungal superinfections and empiric antibiotherapies were revised according to the culture results. Diagnosis and grading of acute respiratory distress were done using the Berlin 2015 diagnostic criteria. 10 Patients with elevated daily cardiac-specific troponin levels underwent echocardiographic evaluation for nascent cardiac pathologies.

Coagulopathy was defined as prothrombin and partial thromboplastin 

After 15 minutes of semi-supine rest, blood samples were obtained from an antecubital vein into tubes containing ethylenediaminetetraacetic acid to prevent coagulation. Troponin I concentrations were measured by chemiluminescent immunoassay using an Immulite 2500 (Siemens Medical Solutions, Erlangen, Germany). TREM-1 and TREM-2 concentrations were measured by enzyme-linked immunosorbent assay (Elabscience human ELISA kit, UK).

The data were analysed using IBM SPSS Statistics for Windows version 20.0 (IBM Corp., Armonk, NY). Pearson's chi-square test and Mann-Whitney U test were used for intergroup comparisons of parametric data and non-normally distributed numerical data, respectively. Independent-samples t test was used to compare demographic data and laboratory parameters between the groups.

Wilcoxon analysis was used for intragroup comparisons of laboratory values during follow-up. Receiver operating characteristic (ROC) curve analysis was used to determine whether the TREM-1/TREM-2 ratio had diagnostic value and an optimal cut-off value was determined using Youden index. Pearson correlation analysis was used to evaluate relationships between TREM-1/TREM-2 levels and age, white blood cell (WBC) count, lactose dehydrogenase (LDH), ferritin, and ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (PaO 2 /FiO 2 ). A p-value less than 0.05 was considered statistically significant.

The mean age of the COVID-19 patients was 55.5 ± 14.3 years and that of the control group was 53.4 ± 16.1 years. There was no statistically significant difference in age between the study and control groups (P = .43). The study group included 73 men and 48 women.

Thirty-seven of the 68 patients with moderate COVID-19 and 36 of the 53 patients with severe COVID-19 were men. There was no statistically significant difference in sex between patients with moderate and severe COVID-19 (P = .09).

A comparison of the patients' laboratory data is shown in Table 1 .

Compared with patients with moderate COVID-19, patients with severe illness had significantly lower lymphocyte count and PaO 2 / FiO 2 levels (P = .001, P = .001) and significantly higher neutrophil/ lymphocyte ratio (NLR), LDH, CRP, D-dimer, ferritin and fibrinogen levels (P = .001, P = .001, P = .001, P = .006, P = .001, P = .001, respectively).

The comparison of TREM-1 and TREM-2 levels between the control and patient groups is shown in Table 2 . TREM-1 level was significantly higher in patients with severe illness compared with patients with moderate illness and controls (P = .003, P = .001). TREM-2 levels did not differ significantly between patients with moderate and severe illness (P = .36) but was significantly higher in both patient groups compared with the control group (P = .001 for both).

TREM-1/TREM-2 ratio was significantly higher in the severe patient group than in the moderate and control groups (P = .001 for both). Note: Statistically significant results are indicated in bold.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; GGT, gamma-glutamyl transferase; LDH, lactose dehydrogenase; NLR, neutrophil to lymphocyte ratio; PaO 2 /FiO 2 , ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; SD, standard deviation; WBC, white blood cells. shown to be therapeutically beneficial in many inflammatory conditions, including viral infections. 15, 16 Failure to adequately suppress increased cytokine levels in the lungs with timely treatment leads to alveolar epithelial damage, alveolar septal fibrous proliferation, and hyaline membrane formation. This causes hypoxic respiratory failure or associated complications in a significant proportion of patients, resulting in higher mortality. Surviving patients may require long-term oxygen therapy because of reduced lung compliance. 17 Therefore, restoring the inflammatory/anti-inflammatory balance early and adequately helps prevent mortality and morbidity in COVID-19. 18

The immune system is continuously being stimulated by infec- and TNFα synthesis via NF-κB in patients with acute respiratory distress syndrome. 24 Likewise, pravastatin and azithromycin were also found to significantly decrease proinflammatory cytokine levels, especially TREM-1, when tested in mouse models of atherosclerosis and sepsis, respectively. 25, 26 It was observed that TREM-1-deficient mice had markedly reduced morbidity secondary to viral and parasitic infections, while pathogen clearance was not affected. This led to the conclusion that TREM-1 can be safely targeted as a therapeutic agent. 19 In a study conducted in a mouse sepsis model, abnormal TNFα, IL-1β and IL-6 levels were observed in TREM-2-and DAP12-deficient animals compared with the control group. 34, 35 In our study, we observed that laboratory parameters, such as COVID-19 patients, we found that at the optimal cut-off value of 0.125 determined by Youden index, specificity was higher than sensitivity (71% vs 60%). This suggests that TREM-1/TREM-2 ratio may be more efficient in identifying patients with severe course.

The most important limitation of our study was the inability to investigate whether genetic factors may be responsible for the effects on TREM-1, TREM-2 or DAP12 synthesis. Obtaining these data may also facilitate our ability to maintain the anti-inflammatory balance in COVID-19 and prevent disease progression. Another limitation is that the small patient sample and the few patients with severe illness who died precluded a stronger statistical analysis. However, this can be primarily attributed to reaching patients relatively earlier after disease onset and to the widespread use of systemic steroids in intensive care patients.

In conclusion, anti-inflammatory treatments have yielded positive results and increased survival in COVID-19. Therefore, medical treatments that suppress TREM-1 synthesis or increase TREM-2 expression may have an important role in preventing disease progression. In addition, detecting a high TREM-1/TREM-2 ratio early in the disease may provide early information about progression.

All authors disclosure no Conflict of Interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

The SARS-CoV-2 outbreak: what we know

COVID-19 pathophysiology: A review

Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients

The COVID-19 cytokine storm; what we know so far

TREM and TREM-like receptors in inflammation and disease

TREM-1 promotes survival during septic shock in mice

Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12

Cutting edge: TREM-2 attenuates macrophage activation

Neuroprotective effect of TREM-2 in aging and Alzheimer's disease model

Interobserver reliability of the Berlin ARDS definition and strategies to improve the reliability of ARDS diagnosis

The COVID-19 epidemic

Evaluation of the relationship between laboratory parameters and pulmonary function tests in COVID-19 patients

Acute respiratory distress syndrome after the use of gadolinium contrast agent

Acute respiratory distress syndrome; A rare complication caused by usage of ruxolitinib

Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19?

Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

COVID-19: combining antiviral and anti-inflammatory treatments

Triggering receptor expressed on myeloid cells-1 (TREM-1) as a therapeutic target in infectious and noninfectious disease: a critical review

Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia

TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives

Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors

Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response

Predictors of response to corticosteroid treatment in patients with early acute respiratory distress syndrome: results of a pilot study

Azithromycin acts as an immunomodulatory agent to suppress the expression of TREM-1 in Bacillus pyocyaneus-induced sepsis

Pravastatin sodium attenuated TREM-1-mediated inflammation in human peripheral blood mononuclear cells

Silencing of triggering receptor expressed on myeloid cells-2 enhances the inflammatory responses of alveolar macrophages to lipopolysaccharide

Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12

TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells

Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis

Pattern recognition by TREM-2: binding of anionic ligands

TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria

TREM-2 binds to lipooligosaccharides of Neisseria gonorrhoeae and is expressed on reproductive tract epithelial cells

From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection

Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance